Angiotensin II type 1 receptor blockade attenuates gefitinib-induced cardiac hypertrophy via adjusting angiotensin II-mediated oxidative stress and JNK/P38 MAPK pathway in a rat model

• Main Authors: Wael A. Alanazi (Author), Hussain N. Alhamami (Author), Metab Alharbi (Author), Khalid Alhazzani (Author), Abdulrahman S. Alanazi (Author), Sary Alsanea (Author), Nemat Ali (Author), Abdullah F. Alasmari (Author), Ahmed Z. Alanazi (Author), Moureq R. Alotaibi (Author), Mohammed Alswayyed (Author)
• Format: Book
• Published: Elsevier, 2022-08-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Gefitinib is a tyrosine kinase inhibitor (TKI) of the epidermal growth factor receptor (EGFR), used for the treatment of advanced or metastatic non-small cell lung cancer. Recently, studies proved that Gefitinib-induced cardiotoxicity through induction of oxidative stress leads to cardiac hypertroph...